Rexahn's Akt inhibitor increases pancreatic cancer survival time 50%
This article was originally published in Scrip
Rexahn Pharmaceuticals potential first-in-class inhibitor of the Akt protein kinase in cancer cells, Archexin, provided metastatic pancreatic cancer with a survival rate that was more than 50% higher than historical rates for the standard of care. The data came from a 31-patient Phase IIa clinical trial. The Rockville, Maryland company will have to conduct a Phase IIb study in a larger pool of hard-to-treat patients to try to replicate the survival benefit.
You may also be interested in...
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.